Related Experiment Videos
Experimental otitis media with effusion induced by leukotriene D4
Naoki Tada1, Masayuki Furukawa, Manabu Ogura
1Department of Otorhinolaryngology, Kansai Medical University, 10-15 Fumizono, 570-8506, Moriguchi, Japan. naoki-t@db3.so-net.ne.jp
Auris, Nasus, Larynx
|March 15, 2002
Summary
Leukotrienes (LTs) play a key role in the development of otitis media with effusion (OME). Blocking LTs with pranlukast effectively reduced OME in an experimental rat model, suggesting a therapeutic target.
Area of Science:
- Otolaryngology
- Inflammation Research
- Immunology
Background:
- Inflammatory mediators like prostaglandins, leukotrienes (LTs), and platelet-activating factor are found in middle ear effusions.
- The specific role of LTs in the middle ear cavity remains unclear.
Purpose of the Study:
- To investigate the role of LTs in the pathogenesis of otitis media with effusion (OME).
- To evaluate the efficacy of a leukotriene antagonist in an experimental OME model.
Main Methods:
- Otitis media with effusion (OME) was induced in rats by injecting leukotriene D4 (LTD4) at various concentrations.
- Histological analysis assessed OME severity, and cytokine levels (IL-1β, TNF-α, GRO/CINC-1) in middle ear effusions (MEEs) were measured.
- The therapeutic effect of pranlukast, a specific LTs antagonist, was examined.
Main Results:
- Intra-ear injection of LTD4 induced OME in all rats, with persistent effusion observed for up to 14 days in higher concentration groups.
- Elevated cytokine levels correlated with the persistence of OME.
- Oral administration of pranlukast significantly alleviated experimental OME.
Conclusions:
- Leukotrienes (LTs) are implicated in the pathogenesis of otitis media with effusion (OME).
- LTs antagonists, such as pranlukast, show therapeutic potential for OME treatment.